The Validation Burden on SME Pharma: Why Smaller Companies Pay a Disproportionate Price

The regulatory requirements for computerized system validation do not scale with company size. A 50-person contract development and manufacturing organisation (CDMO) introducing a new chromatography data system faces the same validation obligations as a multinational with thousands of employees and a dedicated validation department.

The requirements are the same. The resources available to meet them are not.

This asymmetry has real consequences. It affects which systems smaller companies adopt, how quickly they can bring those systems into GxP use, and how much of their quality team's time is consumed by documentation rather than the oversight activities that directly protect patients.

For large pharmaceutical companies, validation is handled by dedicated teams, often supported by specialised consultancies and enterprise software platforms. The cost is significant but manageable within the overall quality budget.

For an SME pharma company or CDMO, the picture is different. Consider a company with a quality team of five people responsible for everything from batch release to deviation management to change control. When a new system needs validation, one or two of those team members must take on validation activities alongside their existing responsibilities.

A typical computerized system validation project for a Category 4 system (a configured commercial product, in GAMP 5 terms) involves producing a validation plan, risk assessment, user requirements specification, functional and design specifications, installation and operational qualification protocols, test scripts, traceability matrices, a validation summary report, and supporting documentation for data integrity, electronic signatures, and system administration.

Even for a straightforward system, this documentation package can take weeks to produce. During that time, the quality team members involved have less capacity for their other responsibilities. The validation work does not replace their existing workload. It adds to it.

Many SMEs address this capacity gap by engaging external consultancies. This solves the resourcing problem but introduces others.

Consultancy costs for validation projects typically range from tens of thousands to six figures, depending on the system complexity and documentation scope. For an SME, this represents a significant investment, and one that recurs with every new system, major upgrade, or periodic revalidation.

There is also a knowledge transfer problem. When a consultancy produces validation documentation, the institutional knowledge about why specific decisions were made often leaves with the consultant. The company retains the documents but not always the reasoning behind them. This becomes problematic during inspections, when the company's own quality team must defend validation decisions they did not make.

The most effective consultancy engagements involve close collaboration between the consultant and the company's quality team, ensuring knowledge transfer throughout the project. But this collaborative model requires more of the quality team's time, partially negating the resource benefit of engaging external help.

The practical consequence of limited validation capacity is that system implementations get delayed. A company may identify a clear operational need for a new system, perhaps a quality management system to replace manual processes, or an environmental monitoring system to improve data capture, but the validation effort required to bring that system into GxP use delays the project by months.

During that delay, the company continues to operate with less capable processes. Manual data capture continues. Paper-based quality systems persist. The gap between operational needs and validated capabilities widens.

In some cases, companies choose systems based partly on how simple they will be to validate, rather than which system best serves their operational needs. This is a rational response to resource constraints, but it means the organisation's technology choices are being driven by documentation burden rather than functional requirements.

There is a fundamental tension in traditional CSV approaches: the documentation is meant to provide assurance, but the volume of documentation required can itself become a quality risk.

When a quality team is under pressure to produce validation documentation for multiple systems while maintaining their other responsibilities, the risk of errors in the documentation increases. Templated approaches help with consistency but can also lead to boilerplate content that does not meaningfully address the specific risks of the system being validated.

Regulators are aware of this dynamic. The move toward CSA (Computer Software Assurance) and the emphasis on critical thinking in GAMP 5 Second Edition reflect a recognition that documentation volume is not a proxy for assurance quality. But the transition to risk-based approaches is itself a challenge for smaller organisations that may lack the experience or frameworks to determine how much documentation is "enough."

For independent Qualified Persons (QPs) and small QP consultancies, the validation burden has a direct impact on their ability to serve their clients.

A QP responsible for batch release at a contract manufacturer must have confidence that the computerized systems supporting GxP processes are appropriately validated. If the validation documentation is incomplete, inconsistent, or poorly structured, the QP faces a difficult choice: delay release until the documentation is satisfactory, or accept the documentation as-is and carry the personal risk.

The QP role carries individual legal liability. Every batch release decision is personal. The quality of the validation documentation underlying the computerised systems used in manufacturing directly affects the QP's ability to make informed release decisions with confidence.

This creates a strong incentive for QPs to demand thorough validation documentation. But "thorough" does not have to mean "voluminous." What QPs need is documentation that clearly demonstrates the system meets its requirements, that GxP-critical functions have been adequately tested, and that data integrity controls are in place. They need confidence in the quality of the evidence, not reassurance through quantity.

The disparity between large and small pharma companies in their ability to manage validation is not inevitable. It is a consequence of the tools and processes available.

Large companies can afford enterprise validation management systems, dedicated teams, and specialised training. Small companies rely on Word templates, shared drives, and the institutional knowledge of whoever happens to be available.

AI-powered validation tools have the potential to change this dynamic. Not by eliminating the need for qualified professionals, but by reducing the time and effort required to produce consistent, traceable documentation. If a quality professional at an SME can produce the same quality of validation documentation in days rather than weeks, the capacity constraint eases significantly.

The goal is not to lower the standard of validation. The goal is to make meeting that standard achievable for organisations that cannot dedicate entire teams to the task. World-class validation documentation should not be a privilege of scale.